Mark Smithyes, Chair
Mark was recently appointed President of Labtician Théa, a newly established joint venture between Labtician Ophthalmics and Laboratoires Théa. Labtician is a Canadian leader in bringing innovation to practice for Canadian eye care professionals while Théa is Europe’s largest family-owned ophthalmology company and leader in the development of preservative-free eye care treatments. As President, Mark is building the joint venture to leverage the strengths of both organizations to create Canada’s new leader in the preservative-free management of glaucoma, dry eye disease and lid hygiene. In doing so, the new company is helping Canadian optometrists and ophthalmologists build their practices and preserve eye health for their patients.
Prior to this new challenge, Mark was Head, Pharmaceutical Business Unit at Alcon Canada and was responsible for all aspects of its operational and financial performance. Previously, Mark served as Head of Communications, Government Affairs and Market Access, also at Alcon Canada. In all of these roles, he served as a key member of Alcon’s Senior Leadership Team. These positions are a part of an extensive career in the pharmaceutical industry that includes numerous leadership positions in business management, sales, marketing, government relations, communications and change management over the last 20 years.
Mark is a regular contributor and speaker at industry conferences and has served on a number of industry and community boards. Currently Mark serves as the Chair of the Board of Directors of Life Sciences Ontario.
Mark holds a BA from the University of Western Ontario and an MBA from the Kellogg and Schulich Schools of Business. He lives in Toronto with his wife, Cathy Douglas and his four children.